Allarity raises ~$11M in public offering; reprices warrants, reduces Series A conversion price, redeems 3i holdings

On July 11, 2023, we filed a Third Amendment to change the “Conversion Price” from $8.00 to $4.50.

On July 5, 2023, Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) agreed to sell in a public offering an aggregate of 357,223 shares of Common Stock of the Company (the “Shares”), pre-funded warrants to purchase up to 2,087,222 shares of Common Stock (the “Pre-Funded Warrants”), and common warrants to purchase up to 2,444,445 shares of Common Stock (the “Common Warrants” together with the Shares, the Pre-Funded Warrants and Common Stock issuable upon exercise of the Common Warrants and the Pre-Funded Warrants, collectively, the “Securities”), at an effective combined purchase price of $4.50 per share and related Common Warrant (the “Purchase Price”), for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and offering expenses payable by the Company (the “Offering”). The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto (each, a “Pu

Concurrent with the close of the Offering, the Company entered into an Amended and Restated Common Stock Purchase Warrant to memorialize the repricing and the extension of termination date (“Amended and Restated Warrant”).

Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).